290: Biotech layoffs, slumping stocks, and a 2024 preview
Our colleague Jason Mast joins us to discuss an emerging trend in biotech: Cash-rich startups are laying off employees and tweaking their strategies amid a tough market for venture capital. We also look ahead to the biggest biotech stories coming in 2024, including some major data readouts and a few pivotal FDA decisions.\n\nHere's where you can subscribe to our biotech newsletter, The Readout.